US Artificial Tears Market 2026-2035
Description
US Artificial Tear Market Size, Share & Trends Analysis Report by Type (Cellulose-Derived Tears, Glycerin-Derived Tears, Oil-Based Emulsion Tears, and Polyethylene Glycol- & Propylene Glycol-Based Tears), By Delivery Method (Eyedrops and Ointments/Gel), By Application (Dry Type Treatment, Contact Lens Moisture, and Digital Eye Strain) and By End-User (Retail Pharmacies (OTC), Online Pharmacies, Hospitals & Ophthalmic Clinics, and Other End User) Forecast Period, (2026-2035)
Industry Overview
US artificial tear market was valued at $577.5 million in 2025 and is projected to reach $944.1 million by 2035, growing at a CAGR of 5.1% during the forecast period (2026–2035). The US artificial tear market is witnessing steady growth as ophthalmologists, optometrists, and retail pharmacies increasingly prioritize effective management of dry eye disease and ocular surface disorders. Market expansion is being driven by the rising prevalence of digital eye strain, aging populations, and higher contact lens usage, which collectively boost demand for ocular lubricants. Adoption is further supported by growing awareness of eye health, over-the-counter accessibility, and evolving clinical guidelines recommending early intervention for dry eye management. The market is also benefiting from ongoing product innovations, including cellulose- and glycerin-based formulations, oil-based emulsions, and preservative-free options, along with advanced delivery formats such as gels and multi-dose drop systems that improve patient convenience and compliance.
Market Dynamics
Rising Focus on Digital Eye Strain Management and Ocular Health Awareness
The US artificial tear market is expanding as ophthalmologists, optometrists, and retail pharmacies increasingly emphasize preventive and therapeutic management of dry eye disease and ocular surface disorders. The growing prevalence of digital eye strain, extended screen usage, and contact lens adoption is driving demand for advanced ocular lubricants. Public awareness campaigns, clinical guidelines, and educational initiatives are further promoting early intervention and regular eye care, reinforcing market growth.
Increasing Innovation in Formulations and Delivery Technologies
Advanced formulations, including cellulose-, glycerin-, and oil-based emulsions, along with preservative-free and multi-dose delivery systems, are gaining traction across the US. Both established pharmaceutical companies and emerging ocular health startups are introducing innovative products designed for improved efficacy, patient compliance, and convenience. Developments in gel formulations, ophthalmic inserts, and combination therapies are further expanding treatment options. Strategic partnerships and R&D collaborations are accelerating product innovation, underscoring the US’s strong focus on enhancing ocular health through advanced therapeutics.
Market Segmentation
In the US artificial tear market, the preservative-free drops segment commands the largest and most influential share within the type category. This leadership is driven by a strong clinical preference for safer, irritation-free formulations, particularly for patients requiring frequent or long-term management of dry eye disease. Growing awareness of preservative-related ocular surface damage especially from benzalkonium chloride (BAK) has accelerated the shift toward preservative-free options across the United States. The prevalence of dry eye continues to rise due to aging populations, prolonged digital screen exposure, widespread contact lens use, and increasing rates of refractive and cataract surgeries. These factors collectively reinforce demand for preservative-free artificial tears, which are widely recommended by ophthalmologists and optometrists to minimize inflammation and support healthier tear film restoration.
Eye Drops: Key Segment Driving Market Growth in the US
Within the US artificial tear market, eye drops remain the most dominant and fastest-growing delivery format, acting as the primary driver of market expansion. Their convenience, rapid symptom relief, and high consumer familiarity make eye drops the preferred first-line option for mild to moderate dry eye management. Rising digital eye strain, dry indoor environments, environmental pollutants, and extensive contact lens use have further increased daily reliance on eye drops as a quick, non-invasive hydration solution. Eye-care professionals frequently recommend them due to ease of self-administration, broad OTC availability, and suitability for multiple daily applications, fostering high repeat usage and sustained annual demand. Consequently, eye drops continue to serve as the cornerstone of dry eye therapy, playing a decisive role in shaping the growth trajectory of the US artificial tear market.
Market Players Outlook
The major companies operating in the US artificial tear market include Abbott Laboratories, AbbVie Inc., Alcon Inc., Bausch + Lomb Corporation, Johnson & Johnson, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
Industry Overview
US artificial tear market was valued at $577.5 million in 2025 and is projected to reach $944.1 million by 2035, growing at a CAGR of 5.1% during the forecast period (2026–2035). The US artificial tear market is witnessing steady growth as ophthalmologists, optometrists, and retail pharmacies increasingly prioritize effective management of dry eye disease and ocular surface disorders. Market expansion is being driven by the rising prevalence of digital eye strain, aging populations, and higher contact lens usage, which collectively boost demand for ocular lubricants. Adoption is further supported by growing awareness of eye health, over-the-counter accessibility, and evolving clinical guidelines recommending early intervention for dry eye management. The market is also benefiting from ongoing product innovations, including cellulose- and glycerin-based formulations, oil-based emulsions, and preservative-free options, along with advanced delivery formats such as gels and multi-dose drop systems that improve patient convenience and compliance.
Market Dynamics
Rising Focus on Digital Eye Strain Management and Ocular Health Awareness
The US artificial tear market is expanding as ophthalmologists, optometrists, and retail pharmacies increasingly emphasize preventive and therapeutic management of dry eye disease and ocular surface disorders. The growing prevalence of digital eye strain, extended screen usage, and contact lens adoption is driving demand for advanced ocular lubricants. Public awareness campaigns, clinical guidelines, and educational initiatives are further promoting early intervention and regular eye care, reinforcing market growth.
Increasing Innovation in Formulations and Delivery Technologies
Advanced formulations, including cellulose-, glycerin-, and oil-based emulsions, along with preservative-free and multi-dose delivery systems, are gaining traction across the US. Both established pharmaceutical companies and emerging ocular health startups are introducing innovative products designed for improved efficacy, patient compliance, and convenience. Developments in gel formulations, ophthalmic inserts, and combination therapies are further expanding treatment options. Strategic partnerships and R&D collaborations are accelerating product innovation, underscoring the US’s strong focus on enhancing ocular health through advanced therapeutics.
Market Segmentation
- Based on type, the market is segmented into glycerin-derived tears, cellulose-derived tears, oil-based / emulsion-based tears, polyethylene glycol (PEG)-based tears, propylene glycol-based tears, and hyaluronic acid.
- Based on the delivery mode, the market is segmented into eye drops and ointments.
- Based on the application, the market is segmented into dry eye syndrome, digital eye strain, and contact lens discomfort/moisture retention.
- Based on the end user, the market is segmented into retail pharmacies (OTC), online pharmacies, hospitals & ophthalmic clinics, and others.
In the US artificial tear market, the preservative-free drops segment commands the largest and most influential share within the type category. This leadership is driven by a strong clinical preference for safer, irritation-free formulations, particularly for patients requiring frequent or long-term management of dry eye disease. Growing awareness of preservative-related ocular surface damage especially from benzalkonium chloride (BAK) has accelerated the shift toward preservative-free options across the United States. The prevalence of dry eye continues to rise due to aging populations, prolonged digital screen exposure, widespread contact lens use, and increasing rates of refractive and cataract surgeries. These factors collectively reinforce demand for preservative-free artificial tears, which are widely recommended by ophthalmologists and optometrists to minimize inflammation and support healthier tear film restoration.
Eye Drops: Key Segment Driving Market Growth in the US
Within the US artificial tear market, eye drops remain the most dominant and fastest-growing delivery format, acting as the primary driver of market expansion. Their convenience, rapid symptom relief, and high consumer familiarity make eye drops the preferred first-line option for mild to moderate dry eye management. Rising digital eye strain, dry indoor environments, environmental pollutants, and extensive contact lens use have further increased daily reliance on eye drops as a quick, non-invasive hydration solution. Eye-care professionals frequently recommend them due to ease of self-administration, broad OTC availability, and suitability for multiple daily applications, fostering high repeat usage and sustained annual demand. Consequently, eye drops continue to serve as the cornerstone of dry eye therapy, playing a decisive role in shaping the growth trajectory of the US artificial tear market.
Market Players Outlook
The major companies operating in the US artificial tear market include Abbott Laboratories, AbbVie Inc., Alcon Inc., Bausch + Lomb Corporation, Johnson & Johnson, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In September 2025, Bausch + Lomb launched a next-generation preservative-free artificial tear line in the United States, featuring advanced multi-dose packaging designed to enhance convenience and reduce contamination risks. The launch highlights ongoing innovation in patient-centric formulations.
- In August 2025, Alcon, Inc. expanded its US artificial tear portfolio with a new lipid-based emulsion drop targeting moderate to severe dry eye, reflecting growing demand for therapeutics addressing evaporative dry eye subtypes.
- In July 2025, Novartis’s Sandoz division entered into a strategic partnership with a US-based biotech firm to develop preservative-free combination drops aimed at post-surgical and chronic dry eye management. The collaboration emphasizes increasing industry focus on advanced and targeted ocular therapies.
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the US artificial tear market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
120 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- US Artificial Tear Market Sales Analysis – Type Delivery Method Application End-User ($ Million)
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Artificial Tear Industry Trends
- 2.2.2. Market Recommendations
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For US Artificial Tear Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For US Artificial Tear Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For US Artificial Tear Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – US Artificial Tear Market Revenue and Share by Manufacturers
- Artificial Tear Product Comparison Analysis
- 4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. AbbVie Inc.
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Alcon Inc.
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Bausch + Lomb Corporation
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. Johnson & Johnson
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration
- 5. US Artificial Tear Market Sales Analysis By Type ($ Million)
- 5.1. Cellulose-Derived Tears
- 5.2. Glycerin-Derived Tears
- 5.3. Oil-Based Emulsion Tears
- 5.4. Polyethylene Glycol- & Propylene Glycol-Based Tears
- 6. US Artificial Tear Market Sales Analysis By Delivery Method ($ Million)
- 6.1. Eyedrops
- 6.2. Ointments/Gel
- 7. US Artificial Tear Market Sales Analysis By Application ($ Million)
- 7.1. Dry Type Treatment
- 7.2. Contact Lens Moisture
- 7.3. Digital Eye Strain
- 8. US Artificial Tear Market Sales Analysis By End-User ($ Million)
- 8.1. Retail Pharmacies (OTC)
- 8.2. Online Pharmacies
- 8.3. Hospitals & Ophthalmic Clinics
- 8.4. Other End User
- 9. Company Profiles
- 9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
- 9.2. AbbVie Inc.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
- 9.3. Akorn, Inc.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
- 9.4. Alcon Inc.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
- 9.5. Bausch + Lomb Corporation
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
- 9.6. Bayer AG
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
- 9.7. Clear Eyes
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
- 9.8. Eyevance Pharmaceuticals LLC
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
- 9.9. Johnson & Johnson Vision
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
- 9.10. Novartis AG
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
- 9.11. OcuSOFT, Inc.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
- 9.12. Otsuka Pharmaceutical Co., Ltd.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
- 9.13. Prestige Consumer Healthcare, Inc.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
- 9.14. Roche
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
- 9.15. Rohto Pharmaceutical Co., Ltd.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
- 9.16. Sager Pharma
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
- 9.17. Santen Pharmaceutical Co., Ltd.
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
- 9.18. Similasan Corporation
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
- 9.19. Sun Pharmaceutical Industries Ltd.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
- 9.20. Ursapharm Arzneimittel GmbH
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
